LPCN Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Lipocine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.57 |
| 52 Week High | US$7.15 |
| 52 Week Low | US$2.31 |
| Beta | 1.11 |
| 1 Month Change | 29.59% |
| 3 Month Change | 68.46% |
| 1 Year Change | 28.07% |
| 3 Year Change | -68.06% |
| 5 Year Change | -75.38% |
| Change since IPO | -98.07% |
Recent News & Updates
Recent updates
Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%
Sep 26Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?
Feb 22
Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?
Sep 14Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression
Jun 14Lipocine competitor prevails in patent infringement lawsuit for Jatenzo
May 26When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?
May 11Lipocine EPS beats by $0.01
May 06Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?
Jan 26Lipocine announces positive results from phase 2biopsy-confirmed NASH study
Jan 12FDA Ok's Lipocine's testosterone replacement therapy, tentatively
Dec 09Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?
Dec 04
Lipocine EPS misses by $0.01
Nov 10Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection
Nov 06Shareholder Returns
| LPCN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 16.9% | 1.9% | 1.2% |
| 1Y | 28.1% | 16.7% | 27.7% |
Return vs Industry: LPCN exceeded the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: LPCN matched the US Market which returned 27.7% over the past year.
Price Volatility
| LPCN volatility | |
|---|---|
| LPCN Average Weekly Movement | 13.0% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LPCN's share price has been volatile over the past 3 months.
Volatility Over Time: LPCN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 17 | Mahesh Patel | www.lipocine.com |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor.
Lipocine Inc. Fundamentals Summary
| LPCN fundamental statistics | |
|---|---|
| Market cap | US$35.14m |
| Earnings (TTM) | -US$8.97m |
| Revenue (TTM) | US$4.71m |
7.5x
P/S Ratio-3.9x
P/E RatioIs LPCN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LPCN income statement (TTM) | |
|---|---|
| Revenue | US$4.71m |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.71m |
| Other Expenses | US$13.68m |
| Earnings | -US$8.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -190.35% |
| Debt/Equity Ratio | 0% |
How did LPCN perform over the long term?
See historical performance and comparison